Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans ...
· Eliquis demonstrated noninferiority in the primary efficacy endpoint of recurrent symptomatic venous thromboembolism (VTE) or VTE-related death versus enoxaparin/warfarin in the AMPLIFY trial · ...
Pfizer, in collaboration with Bristol Myers Squibb, has introduced a direct-to-patient option for Eliquis®, potentially enhancing patient access and affordability. Over the past quarter, Pfizer's ...
Switching from Eliquis (apixaban) to rivaroxaban in Non-Valvular Atrial Fibrillation (NVAF) patients was associated with a higher risk of stroke/systemic embolism (S/SE) and major bleeding (MB) than ...
Princeton, NJ and New York, NY - The US FDA has requested more information from Bristol-Myers Squibb and Pfizer for the new anticoagulant apixaban (Eliquis) for the indication of prevention of stroke ...
Eliquis 360 Support Program Now Offers Eliquis to Cash-Paying Patients at More than 40% Discount to Current List Price PRINCETON, N.J.--(BUSINESS WIRE)-- The Bristol Myers Squibb-Pfizer (BMS NYSE: BMY ...
Please provide your email address to receive an email when new articles are posted on . Apixaban was not superior to standard of care antithrombotic treatment for preventing thrombotic or bleeding ...
The eagerly awaited findings of the ARISTOTLE trial were presented at the 2011 European Society of Cardiology Congress in Paris, France, and simultaneously published online in the New England Journal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback